Brii Biosciences Limited (HK:2137) has released an update.
Brii Biosciences Limited announced positive outcomes from two Phase 2 clinical trials at the European Association for the Study of the Liver Congress 2024, demonstrating that their therapeutic vaccine BRII-179, in combination with other treatments, shows promise for improving immune response and viral control in chronic hepatitis B virus (HBV) patients. The studies suggest that BRII-179 could be a key component in achieving a functional cure for HBV, with a favorable benefit-risk profile justifying further clinical exploration. Investors are cautioned, however, that the successful development and marketing of BRII-179 are not yet assured.
For further insights into HK:2137 stock, check out TipRanks’ Stock Analysis page.
